Skip to content

A Multicenter, Randomized, Crossover, Placebo-Controlled, Superiority Clinical Trial Protocol to Evaluate the Efficacy and Safety of cellulose enhancing capsules

A Multicenter, Randomized, Crossover, Placebo-Controlled, Superiority Clinical Trial Protocol to Evaluate the Efficacy and Safety of cellulose enhancing capsules

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127217
Enrollment
Unknown
Registered
2026-06-26
Start date
2025-05-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Interventions

Experimental group:receives a cellulose enhancing capsules (composed of cross-linked hydrogel particles and a gelatin capsule shell)
Control group:receives cellulose enhancing capsules (Placebo) (composed of edible corn starch and a gelatin capsule shell)

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18 to 80 years; 2. Individuals considered by the investigator to have a need for weight control through dietary reduction; 3. Body mass index (BMI) between 25 kg/m² and 40 kg/m² (25 = BMI < 40); 4. Voluntarily sign the informed consent form and agree to complete the scheduled follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Patients with acute gastrointestinal diseases; 2. Patients currently receiving other weight-loss treatments; 3. Patients with diabetes mellitus; 4. Participation in another clinical trial within 1 month prior to signing informed consent; 5. Pregnant or breastfeeding women, or those planning to become pregnant during the trial period; 6. Allergy to cellulose; 7. Patients with AIDS or a history of cancer within the past 5 years; 8. Renal insufficiency (abnormal serum creatinine); 9. Hepatic impairment: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3× upper limit of normal, or total bilirubin (TBIL) > 3 × upper limit of normal; 10. Any other condition that the investigator deems unsuitable for participation in this trial.

Design outcomes

Primary

MeasureTime frame
Mean Hunger Score;

Secondary

MeasureTime frame
Gastric Emptying Time;Appetite Score;Percentage of Body Weight Loss;

Countries

China

Contacts

Public ContactShen Qu

Shanghai Tenth People's Hospital

qushencn@hotmail.com+86 135 8579 2519

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026